Iqirvo PBC denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Iqirvo in PBC

Prior authorization (PA) for Iqirvo is Aetna's standard administrative gatekeeping mechanism for specialty drugs used in primary biliary cholangitis. The PA requirement is not a denial on the merits — it is a process requirement. However, if the PA was denied (rather than simply never submitted), you are in an appeal situation and have the right to challenge that denial.

PA denials for Iqirvo most often occur because the initial submission did not include the full documentation Aetna requires: confirmation of the PBC diagnosis, evidence of prior treatment and inadequate response, and clinical severity data. A thorough resubmission or formal appeal will address each of these gaps directly.

## Your Federal Appeal Rights

• ERISA §503: A denied PA triggers your full-and-fair review rights. The internal appeal clock for PA denials is shorter than for retrospective denials — confirm the deadline in your denial letter.
• ACA §2719 external review: Available after internal appeal exhaustion. The external-review window is generally four months from the denial notice. If your health situation is urgent — for example, disease progression is accelerating — request expedited external review (typically resolved within 72 hours).
• Concurrent external review: In some states, you may be able to file for external review simultaneously with your internal appeal rather than waiting.

## Concrete Appeal Steps

1. Obtain the PA denial letter — it must state the specific criteria not met. 2. Download Aetna's current Medical Policy (Clinical Policy Bulletin) for Iqirvo or PBC second-line therapies to see exactly what is required. 3. Work with your prescriber to compile the complete documentation package. 4. Resubmit as a formal PA appeal (not merely a new PA request), citing each denial criterion and the evidence that meets it. 5. Track the appeal deadline carefully — missing it forfeits your right to external review.

## Documentation to Gather

• Diagnosis confirmation: AMA serology, liver biopsy if available, specialist consultation notes unambiguously stating the PBC diagnosis.
• Prior treatment documentation: A medication history showing the names, start dates, durations, and clinical outcomes of prior PBC-indicated therapies, with notes on why each was inadequate (intolerance, insufficient response, or other clinical reason).
• Current disease status: Recent liver function tests, liver stiffness measurements, imaging reports, and clinical notes reflecting current disease severity and trajectory.
• Prescriber medical-necessity letter: Should be specific to this patient, referencing the clinical facts in the chart rather than boilerplate language, and should map to Aetna's stated PA criteria.
• FDA prescribing label: Confirms the approved indication; your documentation should show your case falls squarely within it.

## Criteria-Mapping Structure

Obtain Aetna's PA criteria in writing. Build a point-by-point mapping table:

| Aetna PA Criterion | Supporting Documentation | |---|---| | [Each requirement verbatim from Aetna policy] | [Exact chart note, lab result, date, or prescriber statement] |

Submitting this table with your appeal — rather than a narrative letter alone — makes it very difficult for a reviewer to deny the appeal without explaining why specific documented facts are insufficient.